We are live on !
Find out more
Jim Simons Renaissance Technologies
AUM
$72.6B
Turnover
31.08%
1-Year Est. Return
54.88%
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
This Fund
S&P 500
This Quarter Est. Return
+24.48%
1 Year Est. Return
+54.88%
3 Year Est. Return
+169.34%
5 Year Est. Return
+186.18%
10 Year Est. Return
+887.93%
AUM
$72.6B
AUM Growth
+$8.69B
(+14%)
Cap. Flow
+$958M
Cap. Flow % of AUM
Cap. Flow %
1.32%
Top 10 Holdings %
Top 10 Hldgs %
12.01%
Holding
3,761
New
548
Increased
1,084
Reduced
1,502
Closed
621
Avg Time Held
3.5
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 2 |
NVIDIA
NVDA
|
+$938M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$639M |
| 4 |
Netflix
NFLX
|
+$598M |
| 5 |
Amazon
AMZN
|
+$575M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$1.46B |
| 2 |
Sandisk
SNDK
|
+$1.13B |
| 3 |
Apple
AAPL
|
+$426M |
| 4 |
Linde
LIN
|
+$316M |
| 5 |
Vertiv
VRT
|
+$297M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.58% |
| 2 | Healthcare | 14.83% |
| 3 | Consumer Discretionary | 11.24% |
| 4 | Industrials | 10.49% |
| 5 | Communication Services | 8.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3051
Skillful Craftsman
EDTK
$14.8M
| $47.7K | ﹤0.01% |
48,600
-14,200
| -23% | -$14.1K |
2021 Q2
20 quarters
|
|
3052
Jyong Biotech
MENS
$143M
| $47.4K | ﹤0.01% |
+22,900
| New | +$48.6K |
2026 Q2
0 quarters
|
|
3053
Regentis Biomaterials
RGNT
$10.6M
| $47.1K | ﹤0.01% |
+13,348
| New | +$38.1K |
2026 Q2
0 quarters
|
|
3054
Harte-Hanks
HHS
$32.5M
| $46.2K | ﹤0.01% |
21,400
-800
| -4% | -$2.09K |
2022 Q1
17 quarters
|
|
3055
17 Education & Technology Group
YQ
$32.1M
| $45.2K | ﹤0.01% |
20,530
-25,757
| -56% | -$57.9K |
2021 Q3
19 quarters
|
|
3056
Enveric Biosciences
ENVB
$6.31M
| $44.2K | ﹤0.01% |
+32,058
| New | +$77K |
2026 Q2
0 quarters
|
|
3057
TELA Bio
TELA
$45.1M
| $43.6K | ﹤0.01% |
58,100
+5,500
| +10% | +$4.5K |
2024 Q2
8 quarters
|
|
3058
Matinas BioPharma
MTNB
$1.58M
| $43.5K | ﹤0.01% |
4,736
+2,831
| +149% | +$27.4K |
2024 Q4
6 quarters
|
|
3059
Wing Yip Food Holdings
WYHG
$107M
| $43K | ﹤0.01% |
10,596
+1,496
| +16% | +$4.83K |
2025 Q3
3 quarters
|
|
3060
Nasus Pharma
NSRX
$38.3M
| $42.7K | ﹤0.01% |
+12,200
| New | +$35.7K |
2026 Q2
0 quarters
|
|
3061
Mercer International
MERC
$13.1M
| $41.3K | ﹤0.01% |
62,511
+46,500
| +290% | +$46.3K |
2014 Q3
47 quarters
|
|
3062
Estrella Immunopharma
ESLA
$15.3M
| $40.7K | ﹤0.01% |
39,100
-23,695
| -38% | -$31K |
2025 Q3
3 quarters
|
|
3063
Co-Diagnostics
CODX
$4.44M
| $38.8K | ﹤0.01% |
+12,500
| New | +$38.5K |
2026 Q2
0 quarters
|
|
3064
Pluri
PLUR
$11.5M
| $38.3K | ﹤0.01% |
18,324
-1,100
| -6% | -$3.15K |
2021 Q1
21 quarters
|
|
3065
Cytosorbents Corp
CTSO
$15.6M
| $37.4K | ﹤0.01% |
5,001
-35
| -0.7% | -$370 |
2022 Q1
17 quarters
|
|
3066
Metalpha Technology Holding
MATH
$51.8M
| $36.1K | ﹤0.01% |
37,424
-8,676
| -19% | -$9.14K |
2026 Q1
1 quarter
|
|
3067
Oxbridge Re Holdings
OXBR
$8.22M
| $36K | ﹤0.01% |
35,000
+2,300
| +7% | +$2.1K |
2024 Q4
6 quarters
|
|
3068
JE Cleantech Holdings Limited Class A Ordinary Shares
JCSE
$8.35M
| $35.8K | ﹤0.01% |
+25,230
| New | +$31.9K |
2026 Q2
0 quarters
|
|
3069
Siebert Financial
SIEB
$78.3M
| $34.6K | ﹤0.01% |
21,000
-800
| -4% | -$1.46K |
2024 Q2
8 quarters
|
|
3070
uCloudlink Group
UCL
$9.1M
| $33.8K | ﹤0.01% |
36,005
-56,950
| -61% | -$64.4K |
2021 Q4
18 quarters
|
|
3071
Pasithea Therapeutics
KTTA
$13.7M
| $33.8K | ﹤0.01% |
65,600
-27,799
| -30% | -$19.1K |
2026 Q1
1 quarter
|
|
3072
Xos
XOS
$41.2M
| $32K | ﹤0.01% |
+10,600
| New | +$25.9K |
2026 Q2
0 quarters
|
|
3073
Direxion Daily AMD Bear 1X ETF
AMDD
$28.2M
| $31K | ﹤0.01% |
1,170
-130
| -10% | -$5.92K |
2026 Q1
1 quarter
|
|
3074
TaoWeave Inc
TWAV
$5.78M
| $29.5K | ﹤0.01% |
21,400
-38,000
| -64% | -$61K |
2025 Q2
4 quarters
|
|
3075
Neonode
NEON
$13.7M
| $29.3K | ﹤0.01% |
31,168
-16,535
| -35% | -$24.6K |
2026 Q1
1 quarter
|
|
Similar funds
Jim Simons's Q2 2026 Portfolio in Review
As of Q2 2026, Jim Simons held 3,761 positions worth $72.6B, up 14% from $63.9B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q2 2026 filing shows 548 new, 1,084 increased, 1,502 reduced and 621 closed positions. Its largest new stake was Amazon: 2,290,710 shares worth $546M. The largest sale was Micron Technology, an estimated $1.46B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q2 2026 buy was Amazon: 2,290,710 shares worth $546M.
- Jim Simons added most to Meta Platforms (Facebook) in Q2 2026, an estimated $1.08B increase.
- Jim Simons's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $1.46B.
- Jim Simons fully exited Applovin in Q2 2026, selling an estimated $174M.
- Jim Simons's ten largest holdings make up 12% of its $72.6B portfolio in Q2 2026.
- Jim Simons opened 548 new positions and closed 621 in Q2 2026.
- Jim Simons's portfolio value rose 14% quarter-over-quarter to $72.6B.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.